

## **EXHIBIT 7**

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

In re: Seroquel XR (Extended Release  
Quetiapine Fumarate) Antitrust Litig.

Master Dkt. No. 20-1076-CFC

This Document Relates To:

All Direct Purchaser Class Actions

**DECLARATION RELATED TO PROPOSED SETTLEMENT ALLOCATION PLAN**

**Dr. Russell L. Lamb  
President**

Monument Economics Group, LLC  
1000 Wilson Boulevard  
Suite 2650  
Arlington, VA 22209

May 29, 2025

## **I. Introduction and Assignment**

1. I filed several prior reports in this case on behalf of the Direct Purchaser Class Plaintiffs (“Plaintiffs”), each of which listed my background and qualifications. My prior reports include my Expert Report dated September 20, 2023 (“Lamb Report”)<sup>1</sup>, my Supplemental Expert Report dated October 6, 2023 (“Lamb Supplemental Report”),<sup>2</sup> and my Expert Reply Report dated February 1, 2024 (“Lamb Reply Report”).<sup>3</sup> I was also deposed on April 4, 2024.<sup>4</sup> An updated copy of my C.V., including a list of the matters in which I have submitted expert testimony in the past four years, is attached to this Declaration as Appendix A. Monument Economics Group is being compensated for my work in this matter at my usual and customary rate of \$850 per hour.

2. I have been asked by Counsel for the Plaintiffs to develop a methodology that can be used to allocate the Net Settlement Fund<sup>5</sup> to members of the Class<sup>6</sup> who submit claims as part of the claims process in a timely manner (“Claimants”). I describe this methodology in detail below.

## **II. Relevant Background**

3. As discussed above, I previously issued three expert reports in this matter that addressed, among other issues, class certification and the amount of aggregate Class damages. As relevant

---

<sup>1</sup> United States District Court for the District of Delaware, *In Re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation*, Expert Report of Russell L. Lamb, Ph.D., September 20, 2023.

<sup>2</sup> United States District Court for the District of Delaware, *In Re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation*, Supplemental Expert Report of Russell L. Lamb, Ph.D., October 6, 2023.

<sup>3</sup> United States District Court for the District of Delaware, *In Re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation*, Expert Reply Report of Russell L. Lamb, Ph.D., February 1, 2024.

<sup>4</sup> Deposition of Russell Lamb, April 4, 2024.

<sup>5</sup> I understand that the “Net Settlement Fund” includes the \$51,419,000 received in the settlements with (a) AstraZeneca Pharmaceuticals L.P., AstraZeneca UK Limited (collectively “AstraZeneca”), and (b) Handa Pharmaceuticals, LLC (“Handa”), plus any interest earned on the settlement funds, and net of Court-approved attorneys’ fees, any Court-approved Named Plaintiff service awards, and Court-approved expenses, including settlement-related costs and expenses.

<sup>6</sup> On February 6, 2024, the Court certified the “Class” in this matter as: “All persons or entities in the United States, including its territories, possessions, and the Commonwealth of Puerto Rico, who purchased 50mg, 150mg, 200mg, and/or 300mg strength of brand or generic Seroquel XR directly from any of the Defendants at any time from August 2, 2015 until April 30, 2017 (the “Class Period”). Excluded from the Class are Defendants and their officers, directors, management and employees, predecessors, subsidiaries and affiliates, and all federal governmental entities.” United States District Court for the District of Delaware, *In Re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation*, Order Granting Direct Purchaser Class Plaintiffs’ Motion for Class Certification, February 6, 2024 at ¶1. “Defendants” are AstraZeneca, Handa, and Par Pharmaceutical, Inc. (“Par”). Also excluded from the Class for purposes of these Settlement Agreements are the following entities that previously opted out of the Class: Walgreen Co., The Kroger Co., Albertsons Companies, Inc., H-E-B, L.P., Hy-Vee, Inc., CVS Pharmacy, Inc., Rite Aid Corp., and Rite Aid Hdqtrs. Corp (the “Retailer Plaintiffs”).

to this Declaration, I previously calculated the aggregate Class damages (after excluding damages incurred by the Retailer Plaintiffs) in the amount of \$449 million.<sup>7</sup> \$52 million of the aggregate Class damages (or 11.6 percent of the aggregate Class damages) were incurred on the Class's generic Seroquel XR purchases (that is, Generic-Generic or "G-G" Damages) and \$397 million of the aggregate Class damages (or 88.4 percent of the aggregate Class damages) were incurred on the Class's purchases of brand Seroquel XR (the Brand-Generic or "B-G" Damages).<sup>8</sup> The different percentages reflect the fact that damages on brand purchases were calculated as the difference between the high brand price and the much lower generic price; while damages on generic purchases were calculated as the difference between the (already low) generic price and the even lower generic price that would have prevailed with earlier generic competition. These damages calculations utilized sales data produced by AstraZeneca for brand Seroquel XR and by Par and other generic manufacturers for generic Seroquel XR.<sup>9</sup>

4. Several dates and time periods utilized in my prior damages calculations are relevant to the proposed allocation method. In my prior damages calculations, I measured "Brand-Generic" damages from August 2, 2015 through December 31, 2018 and "Generic-Generic" damages from November 1, 2016 through April 30, 2017.<sup>10</sup>

### **III. Methodology for Net Settlement Fund Allocation**

5. The methodology I have developed for purposes of allocating the Net Settlement Fund calculates each Claimant's share of the Net Settlement Fund, *pro rata*, based on the amount of direct purchases<sup>11</sup> of (1) brand Seroquel XR 50mg, 150mg, 200mg, and/or 300mg directly from

---

<sup>7</sup> Lamb Reply Report ¶23, Table 1, Appendix E. These were my calculations for "Scenario 1," which assumes that Par and the Seroquel XR AG would have launched on July 1, 2015, followed by Accord 181 days later on December 29, 2015 for the 150mg, 200mg, and 300mg strengths, with all other generic manufacturers entering the market at the same time they did in the actual world. Lamb Report ¶¶5-10. See also, Lamb Reply Report ¶¶12-13.

<sup>8</sup> Lamb Reply Report ¶23, Table 1, Appendix E.

<sup>9</sup> To exclude the Retailer Plaintiffs' direct purchases, I used the sales data produced by the Defendants and other non-party sellers of generic Seroquel XR. To exclude the Retailer Plaintiffs' assigned purchases, I relied on data produced in the updated backup to the expert report of Dr. Keith Leffler served by the Retailer Plaintiffs in this matter showing the quantity of purchases by the Retailer Plaintiffs that are covered by an assignment from a proposed Class member. Lamb Reply Report ¶16, footnotes 39 and 41.

<sup>10</sup> Lamb Report ¶¶95-96, footnotes 175-176. I understand Plaintiffs allege that generic Seroquel XR would have launched as early as July 1, 2015 absent the challenged conduct and I previously measured overcharges in my Reports assuming that generic entry would have occurred July 1, 2015, but started measuring damages beginning August 2, 2015, which is the start of the Class Period. Lamb Report ¶95, footnote 175.

<sup>11</sup> Here and throughout this declaration, unless otherwise noted, when I refer to "purchases," I am referring to purchases of 50mg, 150mg, 200mg, and/or 300mg brand or generic Seroquel XR, net of returns or assignments, made directly from AstraZeneca or Par during the relevant time periods. I note that I did not measure damages on

AstraZeneca from August 2, 2015 through December 31, 2018;<sup>12</sup> and (2) generic Seroquel XR 50mg, 150mg, 200mg, and/or 300mg directly from Par from November 1, 2016 through April 30, 2017;<sup>13</sup> as compared to the total purchases (by all Claimants who submit valid, accepted Claim Forms) of (a) brand Seroquel XR 50mg, 150mg, 200mg, and/or 300mg from August 2, 2015 through December 31, 2018; and (b) generic Seroquel XR 50mg, 150mg, 200mg, and/or 300mg from November 1, 2016 through April 30, 2017, respectively. In particular, my methodology for *pro rata* allocation of the Net Settlement Fund to each Claimant is as follows:

- a. Allocation of damages based on generic purchases. Because, as discussed above, 11.6 percent of the Class damages were incurred on generic Seroquel XR purchases, I have devised an allocation plan that will allocate 11.6 percent of the Net Settlement Fund to the Class's generic Seroquel XR purchases by dividing up this 11.6 percent *pro rata* based on each Claimant's tablet purchases of generic Seroquel XR. So, for example, if Claimant "X" purchased 100 tablets of generic Seroquel XR and there were 1,000 total generic Seroquel XR tablets purchased by all Claimants who submitted valid Claim Forms, then, based on its generic Seroquel XR purchases, Claimant X would receive an allocation of 10 percent (100/1,000) of the 11.6 percent of the Net Settlement Fund allocated to generic

---

purchases of brand or generic Seroquel XR in the 400mg strength, so there will be no allocation based on purchases of the 400mg strength. Claimants' *pro rata* share will be based only on Seroquel XR and generic Seroquel XR purchases made directly from AstraZeneca or Par and will not be based on any brand or generic Seroquel XR purchases the Claimants may have purchased directly or indirectly from any other entity (with the exception of Claimants who are filing a Claim Form on the basis of an assignment; these Claimants' shares are discussed in footnote 14, below). In addition, the unit of "purchases" is a tablet. In my opinion, this is the correct unit to use, and all calculations in my prior Reports including overcharges were done on a per tablet basis. For purposes of allocation, a purchase of brand Seroquel XR will be weighted the same regardless of whether it is a 50mg, 150mg, 200mg, or 300mg purchase and a purchase of generic Seroquel will be weighted the same regardless of strength because there was no material difference regarding damages between and among damages on the 50mg, 150mg, 200mg, and/or 300mg strengths according to my damages calculations, and so weighting is not necessary.

<sup>12</sup> August 2, 2015 is the beginning of the Class Period and the beginning of the overcharge period I analyzed in my prior reports. December 31, 2018 is the end of the period for which I measured overcharges on brand Seroquel XR in my previous reports. Lamb Report ¶95, footnotes 175-176. I understand Plaintiffs allege that generic Seroquel XR would have launched as early as July 1, 2015 absent the challenged conduct and I previously measured overcharges in my Reports assuming that generic entry would have occurred July 1, 2015, but started measuring damages beginning August 2, 2015, which is the start of the Class Period. Lamb Report ¶95, footnote 175.

<sup>13</sup> November 1, 2016 is the first date on which generic Seroquel XR was sold according to the sales data produced in this litigation. April 30, 2017 is the end of the period for which I measured overcharges on generic Seroquel XR purchases in my previous reports. Lamb Report ¶96.

Seroquel XR purchases, or 1.16 percent ( $10\% \times 11.6\%$ ) of the Net Settlement Fund.

- b. Allocation of damages based on brand Seroquel XR purchases. Because, as discussed above, 88.4 percent of the Class damages were incurred on brand Seroquel XR purchases, I have devised an allocation plan that will allocate 88.4 percent of the Net Settlement Fund to the Class's purchases of brand Seroquel XR by dividing up this 88.4 percent *pro rata* based on each Claimant's tablet purchases of brand Seroquel XR. So, for example, if Claimant "Z" purchased 200 tablets of brand Seroquel XR and there were 1,000 total brand Seroquel XR tablets purchased by all Claimants who submitted valid Claim Forms, then, based on its brand Seroquel XR purchases, Claimant Z would receive an allocation of 20 percent ( $200/1,000$ ) of the 88.4 percent of the Net Settlement Fund allocated to brand Seroquel XR purchases, or 17.68 percent ( $20\% \times 88.4\%$ ) of the Net Settlement Fund.
- c. Each Claimant's total *pro rata* share. Each Claimant's total *pro rata* share will be the sum of its share allocated on the basis of its brand Seroquel XR purchases (if any) and the sum of its share allocated on the basis of its generic Seroquel XR purchases (if any), as described in the preceding two subsections, removing any purchases for which the rights to damages in this litigation have been assigned by agreement, using data provided by the Claimant or its corresponding assignee.<sup>14</sup>

6. This *pro rata* allocation procedure is similar to court-approved allocation procedures in other cases involving alleged overcharges from delayed generic competition in which I have participated as an expert, including *In re Namenda Direct Purchaser Antitrust Litigation*, 1:15-CV-07488 (Southern District of New York), *In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation*, No. 2:13-MD-02445-MSG (Eastern District of Pennsylvania),

---

<sup>14</sup> Allocations to Claimants whose right to settlement allocation arises by virtue of an assignment would be determined in this same fashion. In these cases, the volumes of brand and generic Seroquel XR purchases used to determine the allocation would be the volumes assigned to the Claimant by an otherwise eligible Class member (and the assignor Class member's brand and generic purchase volumes would be reduced by the same amount). The pre-populated claim forms for Class members that have assigned all or part of their claim by entering known assignment agreements with the Retailer Plaintiffs will exclude purchases that were assigned to the Retailer Plaintiffs under these known assignment agreements.

*KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v. Gilead Sciences, Inc., et al.*, 3:20-CV-06961-EMC (Northern District of California San Francisco Division), and *KPH Healthcare Services, Inc., a/k/a Kinney Drugs, Inc. et al. v Mylan, N.V., et al.*, 2:20-CV-02065-DDC-TJJ (District of Kansas).

7. Using data produced in discovery by Defendants AstraZeneca and Par,<sup>15</sup> I have prepared preliminary calculations of each Class member's (a) net direct purchases of brand Seroquel XR 50mg, 150mg, 200mg, and/or 300mg from AstraZeneca from August 2, 2015 through December 31, 2018; and (b) net direct purchases of generic Seroquel XR 50mg, 150mg, 200mg, and/or 300mg from Par for the period from November 1, 2016 through April 30, 2017. These purchase totals can be used to pre-populate Claim Forms mailed to Class members. In addition, these calculations, in final form (after removal of purchases for which the rights to damages in this litigation have been assigned by agreement, using data provided by the Claimant or its corresponding assignee (as described above in paragraph 5(c)), would then serve as the basis for the calculations of allocation percentages described above.

8. I understand that Lead Class Counsel are proposing an option for Claimants to submit their own purchase data should they wish. To the extent submissions from individual Claimants differ from transaction data provided by AstraZeneca or Par, I will review the available data and documentation and confer with the claims administrator and Lead Class Counsel in order to finalize the calculations. In addition, in finalizing my calculations, I will also account for any assignments identified during the claims administration process and/or the extent to which not all Class members file claims (which would cause the *pro rata* shares of Claimants who do file valid, accepted claims to increase). My final calculations will assign *pro rata* shares only to those Claimants who submit a valid, accepted Claim Form (and will not assign *pro rata* shares of the Net Settlement Fund to, for example, a Class member that does not submit a Claim Form).


9. In my opinion, this allocation methodology is practical and efficient for purposes of allocation of the Net Settlement Fund to Claimants. As I discussed, this methodology uses actual

---

<sup>15</sup> I also used the data produced by AstraZeneca and Par to exclude the Retailer Plaintiffs' direct purchases of brand and generic Seroquel XR during the relevant time period. To exclude the Retailer Plaintiffs' assigned purchases, I relied on data produced in the updated backup to the expert report of Dr. Keith Leffler served by the Retailer Plaintiffs in this matter showing the quantity of purchases by the Retailer Plaintiffs that are covered by an assignment from a proposed Class member. Lamb Reply Report ¶16, footnotes 39 and 41.

brand and generic Seroquel XR sales data already produced by AstraZeneca and Par — the same data I used in calculating aggregate Class overcharges. In addition, as noted above, this allocation method employs allocation approaches similar to those approved by courts in other similar cases. Finally, this method provides a fair and reasonable procedure, in my opinion, for distributing the Net Settlement Fund and reimbursing Claimants. It reflects the type and approximate extent of their injury as alleged (according to my prior overcharge calculations) and does not systematically favor recovery (relative to actual overcharges) on the part of potential Claimants who purchased brand Seroquel XR or generic Seroquel XR.

10. The foregoing is true and correct to the best of my knowledge and belief.

A handwritten signature in black ink, reading "Russell L. Lamb Ph.D.", written over a horizontal line.

Russell L. Lamb, Ph.D.

May 29, 2025

# Appendix A



---

## Russell Lamb, Ph.D.

President  
Monument Economics Group  
Email: rlamb@megconsulting.com

### **Professional Summary**

Russell Lamb is an expert in antitrust economics and has testified concerning antitrust liability, impact, and damages. He has an extensive background in applied econometrics and has developed econometric models to measure damages in a number of matters involving allegations of horizontal price fixing. He has provided expert testimony in State and Federal Courts in the United States and in Canada on a range of issues including class-certification and economic damages in antitrust, RICO and consumer fraud matters. In addition, he has provided expert advice to client attorneys at all levels of the litigation. Dr. Lamb has an extensive background in the analysis of domestic and international agricultural markets and has authored more than 50 articles in peer-reviewed economics journals, trade press, and major newspapers.

Dr. Lamb's work has been cited by courts in certifying classes in the United States and Canada. For example, in *In re Aftermarket Automotive Lighting Products Antitrust Litigation*, the court held that his analysis provided "a sufficient basis from which to conclude that Plaintiffs would adduce common proof concerning the effect of Defendants' alleged price-fixing conspiracy on prices class members paid." In certifying the Class in *In re: Titanium Dioxide Antitrust Litigation*, the Court said, "This Court finds that Dr. Lamb's regression analysis accurately reflects the characteristics of the titanium dioxide industry, and the facts in this case." In *In Re: Domestic Drywall Antitrust Litigation*, the Court cited extensively to Dr. Lamb's analysis in its decision to certify the Class: "Dr. Lamb's expert opinion fits the facts of the case, is relevant, and is therefore admissible to show classwide injury and measurable damages in support of Plaintiffs' Motion for Class Certification. [...]"

The Court [...] has thoroughly considered Dr. Lamb's opinion in its decision on the DPPs' Class Certification Motion." In the Canadian LCD Competition Act Class Action, the Court held that Dr. Lamb's analysis provided "evidence of a viable methodology for the determination of loss on a class-wide basis." In *In re: Puerto Rican Cabotage Litigation*, the Court held that "Dr. Lamb [had] set forth a reputable and workable model for determining damages as to individual class members." In certifying the class in *Clarke and Rebecca Wixon, et al. v. Wyndham Resort Development Corp., et al.*, the Court held that "Dr. Lamb [had] presented a plausible class-wide method of proof." In certifying the class in *Eugene Allan, et al., v. Realcomp II, Ltd., et al.*, the Court held that "the Plaintiffs have produced sufficient evidence that common proofs will yield a finding of class-wide damages that predominates over any specific individualized damages. The Lamb Report and Lamb Reply are sufficient to establish this fact." Furthermore, Dr. Lamb was the Indirect Purchaser Plaintiffs' expert in the *In re: Polyurethane Foam Antitrust Litigation* matter, which was certified by the Court in April 2014.

With regard to agricultural economics, Dr. Lamb has a particular expertise in agricultural markets and has undertaken extensive original research and econometric analysis on markets for agricultural commodities. His articles on agricultural economics have been published in peer-reviewed journals, trade press, and major newspapers. Dr. Lamb regularly presents at conferences on topics including the state of the U.S. Economy and farm policy.

Prior to co-founding Monument Economics Group, Dr. Lamb was a Senior Vice President at Nathan Associates Inc., where he directed the firm's litigation consulting practice nationally. Dr. Lamb previously served as a Principal at AACG in Arlington, VA, and as Managing Director and DC Office Head at Econ One Research. He earlier served as an Assistant Professor of Agricultural Economics and faculty member of the Graduate Group in Economics at North Carolina State University and as an Economist and Senior Economist in the Federal Reserve System of the United States, at the Federal Reserve Board and the Federal Reserve Bank of Kansas City.

## **Education**

- Ph.D., Economics, University of Pennsylvania, 1994
- M.A., Economics, The University of Maryland, 1989
- B.A., Economics, The University of Tennessee, 1987

## Expert Testimony Offered

### **2025** *Louisiana Wholesale Drug Co., Inc., et al., v. GlaxoSmithKline LLC, et al.*

- United States District Court New Jersey
- Case No. 2:12-cv-995
- Expert Report, March 26, 2025
- Opinion concerning damages issues
- Retained by Berger & Montague, P.C.

### *Pro Slab Inc., et al. v. Argos UISA LLC, et al.*

- United States District Court South Carolina
- Case No. 2:17-cv-03185-BHH
- Expert Report, March 26, 2025
- Testified at deposition, April 11, 2025
- Expert Reply Report, May 27, 2025
- Opinion concerning class certification and damages issues
- Retained by Heins Mills & Olson, P.L.C. and Cohen & Malad, LLP

### *Copperweld Bimetallics, LLC v. Cerro Wire, LLC, et al.*

- United States District Court for the Northern District of Alabama
- Case No. 5:21-cv-01310-MHH
- Expert Report, February 21, 2025
- Opinion concerning merits and damages issues
- Retained by Arnold & Porter Kaye Scholer LLP

### **2024** *Lana Parris v. ZF Firmenich International SA, et al.*

- Ontario Superior Court of Justice
- Court File No. CV-23-00092672-00CP
- Expert Report, October 28, 2024
- Opinion concerning class certification issues
- Retained by Camp Fiorante Matthews Mogerman and Sotos LLP

### *In Re Cattle and Beef Antitrust Litigation*

- United States District Court for the District of Minnesota
- Case No. 22-md-03031 (JRT/JFD)
- Expert Report, September 25, 2024
- Testified at deposition, December 18, 2024
- Expert Reply Report, April 4, 2025
- Opinion concerning class certification and damages issues
- Retained by Cafferty Clobes Meriwether & Sprengel LLP and Scott+Scott Attorneys at Law LLP

### **2023** *In Re: Generic Pharmaceuticals Pricing Antitrust Litigation*

### *In Re: Clobetasol Cases*

- United States District Court for the Eastern District of Pennsylvania
- Case No. 2:16-CB-27242
- Expert Report, November 1, 2023
- Testified at deposition, January 5, 2024
- Testified at deposition, January 12, 2024
- Expert Reply Report, May 3, 2024
- Opinion concerning class certification issues
- Retained by Fine, Kaplan and Black, R.P.C

*In Re: Generic Pharmaceuticals Pricing Antitrust Litigation*

*In Re: Clomipramine Cases*

- United States District Court for the Eastern District of Pennsylvania
- Case No. 2:16-CM-27242
- Expert Report, November 1, 2023
- Testified at deposition, January 5, 2024
- Testified at deposition, January 12, 2024
- Expert Reply Report, May 3, 2024
- Opinion concerning class certification issues
- Retained by Fine, Kaplan and Black, R.P.C

*KPH Healthcare Services, Inc. et al. v Mylan, N.V., et al.*

- United States District Court for the District of Kansas
- Civil Action No. 2:20-cv-02065
- Expert Declaration, October 10, 2023
- Opinion concerning class certification and damages issues
- Retained by Roberts Law Firm, P.A.

*In Re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation*

- United States District Court for the District of Delaware
- Master Dkt No. 20-1076-CFC
- Expert Report, September 20, 2023
- Supplemental Expert Report, October 6, 2023
- Expert Reply Report, February 1, 2024
- Testified at deposition, April 4, 2024
- Opinion concerning class certification and damages issues
- Retained by Berger & Montague, P.C. and Garwin Gerstein & Fisher LLP

*In Re: Pork Antitrust Litigation*

- United States District Court of Minnesota
- Case No. 0:18-cv-01776
- Expert Report, June 16, 2023
- Expert Reply Report, March 28, 2024
- Testified at deposition, June 4, 2024
- Expert Sur-Reply Report, August 24, 2024

- Opinion concerning merits and damages issues regarding certain Direct Action Plaintiffs
- Retained by Baker Botts L.L.P., Boies, Schiller & Flexner LLP, Carlton Fields, P.A., and Maynard Nexsen PC

*In Re: Evanston Northwestern Healthcare Corporation Antitrust Litigation*

- United States District Court for the Northern District of Illinois Eastern Division
- No. 07-C-4446
- Expert Report, July 28, 2016
- Expert Reply Report, January 25, 2017
- Testified at deposition, September 20, 2016
- Testified at deposition, February 22, 2017
- Expert Declaration, June 23, 2023
- Opinion concerning damages issues
- Retained by Miller Law LLC

*William Rushing, et al. v. Williams-Sonoma, Inc., et al.*

- United States District Court Northern District of California, San Francisco Division
- Case No. 3:16-cv-01421-WHO
- Expert Report, July 25, 2018
- Testified at deposition, January 24, 2023
- Opinion concerning class certification issues
- Retained by Rose Law Group, PC

*In Re Suboxone Direct Purchaser Antitrust Litigation*

- United States District Court for the Eastern District of Pennsylvania
- Case No. 2:13-MD-02445-MSG
- Expert Report, September 18, 2018
- Testified at deposition, October 30, 2018
- Merits Expert Report, November 30, 2018
- Expert Rebuttal Report, January 11, 2019
- Testified at deposition, January 17, 2019
- Expert Merits Rebuttal Report, April 26, 2019
- Testified at deposition, June 12, 2019
- Opinion concerning class certification, merits, and damages issues
- Declaration, October 24, 2023
- Opinion concerning proposed settlement allocation plan
- Retained by Berger & Montague, P.C.; Garwin Gerstein & Fisher LLP; and Faruqi & Faruqi LLP

**2022** *Surgical Instrument Service Company, Inc. v. Intuitive Surgical, Inc.*

- United States District Court Northern District of California
- Case No. 5:21-cv-03496
- Expert Report, December 2, 2022

- Testified at trial, January 14-15, 2025
- Opinion concerning monopolization issues
- Retained by Haley Guiliano LLP

*Anthony Oliver, et al. v. American Express Company, et al.*

- United States District Court Eastern District of New York
- Case No. 1:19-cv-00566
- Expert Report, September 30, 2022
- Supplemental Expert Report, October 19, 2022
- Testified at deposition, January 5, 2023
- Expert Reply Report, March 17, 2023
- Testified at deposition, April 13, 2023
- Testified at evidentiary hearing, July 27, 2023
- Expert Declaration, October 31, 2024
- Opinion concerning class certification and damages issues
- Retained by Berman Tabacco

*Las Vegas Sun, Inc. v. Sheldon Adelson, et al.*

- United States District Court District of Nevada
- Case No. 2:19-cv-01667
- Expert Report, September 19, 2022
- Expert Rebuttal Report, January 18, 2023
- Supplemental Expert Report, April 27, 2023
- Testified at deposition, May 10, 2023
- Opinion concerning damages issues
- Retained by Lewis Roca Rothgerber Christie LLP

*Value Drug Company v. Takeda Pharmaceuticals U.S.A., Inc., et al.*

- United States District Court Eastern District of Pennsylvania
- Case No. 21-CV-3500
- Expert Report, July 25, 2022
- Amended Expert Report, July 28, 2022
- Testified at deposition, August 17, 2022
- Testified at deposition, September 15, 2022
- Testified at class certification hearing, November 1, 2022
- Expert Report, November 17, 2022
- Supplemental Expert Report, December 22, 2022
- Testified at deposition, January 10, 2023
- Expert Report, June 2, 2023
- Testified at deposition, July 11, 2023
- Amended Expert Report, September 3, 2023
- Testified at trial, September 14 and 18, 2023
- Opinion concerning class certification and damages issues
- Retained by Berger & Montague, P.C.

*Serge Asselin v. Ainsi Canada, Inc. et al.*

- Cour Supérieure District de Québec
- Case No. 200-06-000203-169
- Expert Report, May 31, 2022
- Opinion concerning market factors
- Retained by Siskinds LLP, Sotos LLP

*In Re Caustic Soda Antitrust Litigation*

- United States District Court Western District of New York
- Case No. 1:19-cv-00385-EAW-MJR
- Expert Report, April 25, 2022
- Testified at deposition, June 6, 2022
- Expert Reply Report, August 25, 2022
- Testified at deposition, September 23, 2022
- Expert Sur-Rebuttal Report, February 10, 2023
- Testified at class certification hearing, June 5-6, 2023
- Opinion concerning class certification and damages issues
- Retained by CERA LLP

*Boothe Farms, Inc., et al. v. The Dow Chemical Co., et al.*

- United States District Court Eastern District of Arkansas Northern Division
- Case No. 3:19-cv-00264-DPM
- Expert Report, April 15, 2022
- Supplemental Expert Report, April 20, 2022
- Testified at deposition, May 4, 2022
- Declaration, May 19, 2022
- Opinion concerning damages issues
- Retained by Lieff Cabraser Heimann & Bernstein, LLP

**2021** *In Re: Takata Airbag Product Liability Litigation*

- United States District Court Southern District of Florida Miami Division
- MDL No. 2599
- Expert Report, December 23, 2021
- Testified at deposition, January 25, 2022
- Opinion concerning class certification and damages issues
- Retained by Podhurst Orseck

*In Re: Broiler Chicken Antitrust Litigation*

- United States District Court Northern District of Illinois Eastern Division
- Case No. 1:16-cv-08637
- Expert Report, December 20, 2021
- Testified at deposition, February 8, 2022
- Expert Rebuttal Report, July 29, 2022
- Testified at deposition, September 1, 2022

- Expert Declaration, September 5, 2023
- Testified at deposition, September 30, 2023
- Opinion concerning damages issues
- Retained by Polsinelli

*KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. v Gilead Sciences, Inc., et al.*

- United States District Court Northern District of California San Francisco Division
- Case No. 3:20-cv-06961-EMC
- Expert Report, October 19, 2021
- Declaration, February 25, 2022
- Declaration, April 13, 2022
- Declaration, April 26, 2022
- Testified at deposition, May 18, 2022
- Expert Merits Report, June 28, 2022
- Expert Rebuttal Report, June 30, 2022
- Testified at deposition, July 19, 2022
- Testified at deposition, July 25, 2022
- Expert Rebuttal Report, August 12, 2022
- Expert Rebuttal Damages Report, August 16, 2022
- Testified at deposition, August 31, 2022
- Supplemental Expert Report, April 21, 2023
- Opinion concerning class certification and damages issues
- Retained by Roberts Law Firm, P.A.

*In Re: Mallinckrodt plc, et al.*

- United States Bankruptcy Court District of Delaware
- Case No. 20-12522 (JTD)
- Expert Report, August 13, 2021
- Expert Reply Report, August 26, 2021
- Testified at deposition, September 8, 2021
- Supplemental Expert Report, October 29, 2021
- Testified at trial, November 12 and 15, 2021
- Expert Reply Report, December 1, 2021
- Testified at trial, December 16, 2021
- Opinion concerning damages
- Retained by Eimer Stahl LLP and Willkie Farr & Gallagher LLP

*Rebotix Repair LLC v. Intuitive Surgical, Inc.*

- United States District Court Middle District of Florida Tampa Division
- Case No. 8:20-cv-02274-VMC-TGW
- Expert Report, July 26, 2021
- Testified at deposition, October 19, 2021
- Opinion concerning monopolization issues

- Retained by Dovel & Luner

*Irene Breckon and Gregory Sills v. Alsaker AS, et al.*

- Federal Court of Canada
- Court File No. T-1664-19
- Expert Report, July 1, 2021
- Expert Reply Report, July 5, 2022
- Opinion concerning class certification issues
- Retained by Siskinds LLP, Sotos LLP, and Koskie Minsky LLP

*Gazarek Realty Holdings Ltd., et al. v. Corning Incorporated, et al.*

- Ontario Superior Court of Justice
- Court File No. CV-16-549735-00CP
- Expert Report, April 15, 2021
- Opinion concerning class certification issues
- Retained by Camp Fiorante Matthews Mogerman LLP, Sotos LLP, Siskinds LLP

*Kate O'Leary Swinkels v. ZF Friedrichshafen Ag, et al.*

- Ontario Superior Court of Justice
- Court File No. CV-18-00604648-00CP
- Expert Report, April 15, 2021
- Expert Reply Report, January 19, 2022
- Opinion concerning class certification issues
- Retained by Camp Fiorante Matthews Mogerman LLP, Sotos LLP, Siskinds LLP

*In Re Capacitors Antitrust Litigation*

- United States District Court Northern District of California San Francisco Division
- Case No. 3:14-CV-03264 -JD
- Expert Declaration, February 24, 2017
- Expert Reply Declaration, April 28, 2017
- Testified at deposition, May 17, 2017
- Expert Trial Declaration, November 30, 2018
- Expert Trial Reply Declaration, April 19, 2019
- Testified at deposition, May 23, 2019
- Expert Declaration, July 2, 2021
- Opinion concerning class certification issues regarding indirect purchasers
- Retained by Cotchett, Pitre & McCarthy, LLP

*David Regan v. Masonite International Corporation, et al.*

- Federal Court of Canada
- Court File No. T-1049-20
- Expert Report, March 31, 2021
- Expert Reply Report, July 14, 2023
- Opinion concerning class certification issues

- Retained by Siskinds LLP

*In Re: JELD-WEN Holding, Inc. Securities Litigation*

- United States District Court for the Eastern District of Virginia Richmond Division
- Case No. 3:20-CV-00112-JAG
- Expert Declaration, January 4, 2021
- Expert Reply Declaration, February 15, 2021
- Testified at deposition, February 26, 2021
- Opinion concerning anticompetitive conduct issues
- Retained by Labaton Sucharow LLP and Robbins Gellar Rudman & Dowd LLP

**2020** *In Re Namenda Indirect Purchaser Antitrust Litigation*

- United States District Court Southern District of New York
- Case No. 1:15-CV-06549
- Expert Report, July 6, 2020
- Testified at deposition, July 23, 2020
- Expert Reply Report, September 21, 2020
- Opinion concerning class certification and damages issues regarding indirect purchasers
- Retained by Miller Law LLC and Safirstein Metcalf LLP

*In Re: Interior Molded Doors Antitrust Litigation*

- United States District Court for the Eastern District of Virginia Richmond Division
- Case No. 3:18-CV-00718-JAG
- Class Certification and Trial Expert Report, January 31, 2020
- Testified at deposition, March 4, 2020
- Class Certification and Trial Expert Reply Report, June 9, 2020
- Testified at deposition, July 16, 2020
- Opinion concerning class certification and damages issues
- Retained by Spector Roseman Kodroff & Willis, P.C., and Berger & Montague, P.C.

*In Re Zetia (Ezetimibe) Antitrust Litigation*

- United States District Court for the Eastern District of Virginia Norfolk Division
- Case No. 2:18-MD-02836-RBS-DEM
- Expert Declaration, November 18, 2019
- Testified at deposition, December 20, 2019
- Expert Trial Declaration, January 13, 2020
- Expert Reply Declaration, February 20, 2020
- Testified at class certification hearing, May 1, 2020
- Expert Trial Reply Declaration, May 8, 2020
- Expert Supplemental Declaration, May 15, 2020
- Testified at deposition, June 9, 2020
- Opinion concerning class certification and damages issues

- Retained by Miller Law LLC and Motley Rice LLC

*Fady Samaha and Urlin Rent a Car Ltd. v. Yamashita Rubber Co., Ltd., et al.*

- Ontario Superior Court of Justice
- Court File No. CV-13-472262-00CP
- Expert Report, December 4, 2017
- Supplemental Report, July 13, 2018
- Expert Reply Report, January 23, 2020
- Testified at deposition, April 20, 2020
- Supplemental Report, September 30, 2020
- Opinion concerning class certification issues
- Retained by Siskinds LLP

## **Professional Experience**

### **Economic Consulting Positions**

**Monument Economics Group**, Arlington, VA, *President*, Oct. 11, 2016 - Present

**Nathan Associates, Inc.**, Arlington, VA, *Senior Vice President*, Jan. 2013 – Sep. 20, 2016

**Advanced Analytical Consulting Group, Inc.**, Washington, DC, *Principal*, Mar. 2011– Jan. 2013

**Econ One Research, Inc.**, Washington, DC, *Managing Director and DC Office Head*, Jul. 2006 – Mar. 2011

- Opened and staffed the DC office; managed office affairs on a daily basis
- Retained as an expert witness for damages and class certification issues in antitrust, breach of contract, product liability and RICO cases; representative testimony includes determination of liability and damages in a case involving resale price maintenance in consumer products, class certification in a horizontal price-fixing case involving international travel in the airline industry, class certification in a consumer class action involving RICO claims in state court
- Industry pre-litigation analyses for consumer products, chemicals, and other industries

**Navigant Consulting, Inc.**, Washington, DC, *Associate Director*, Feb. 2006 – Jul. 2006

- Case manager for damages analysis in asbestos litigation and personal injury claims

**Nathan Associates, Inc.**, Arlington, VA, *Managing Economist*, Jul. 2004 – Feb. 2006

- Case manager for economic analysis of class certification and damages issues in antitrust and RICO cases involving the chemical, consumer products, and tobacco industries
- Retained as expert on damages for direct purchasers of NBR in the Crompton Global Settlement; submitted an Affidavit on damages and appeared before the Special Master for the Crompton Global Settlement (the Hon. Kenneth Feinberg)

### **Board Membership**

- Board of Advisors, American Antitrust Institute, Washington, DC
- Department of Economics Advisory Council, University of Tennessee, Knoxville, Chairman, Spring 2006 – April 2011

### **Teaching Positions**

- The University of Tennessee, Knoxville, *Adjunct Professor*, Spring 2019 – present
- The George Washington University, Washington, DC, *Adjunct Assistant Professor of Economics*, Fall 2004 – present
- North Carolina State University (NCSU), *Assistant Professor* (Department of Agricultural and Resource Economics), Fall 1999 – Spring 2004
- The University of Pennsylvania, *Adjunct Instructor*, Summer 1990 – Spring 1994

### **Additional Teaching Experience**

- The Wharton School Evening Division, Philadelphia, PA, summer 1993
- Rutgers University, Camden, NJ, summer 1993
- Philadelphia College of Textiles and Science, Philadelphia, PA, fall 1992
- The Pennsylvania State University, Media, PA, 1991
- St. Mary's College of Maryland, St. Mary's City, MD, summer 1989
- The University of Maryland University College, College Park, MD, 1988-1989

### **Courses Taught**

- Managerial Economics for MBA students (George Washington University)
- Law and Economics (George Washington University)
- Intermediate Microeconomics – graduate level (George Washington University)
- Latin American Economic Development (George Washington University)
- International Trade: Theory and Policy (George Washington University)
- International Finance: Theory and Policy (George Washington University)
- Agricultural Production and Supply – Ph.D. field course (North Carolina State University)
- U.S. Agricultural Policy (North Carolina State University)
- Microfinance: Theory, Practice and Regulation (Superintendencia de Banca y Seguros)
- Statistical Analysis for Economics (University of Pennsylvania)
- Principles of Microeconomics (University of Maryland, St. Mary's College of Maryland)

- Principles of Macroeconomics (University of Pennsylvania, The Wharton School, Penn State University)
- Fundamentals of Micro/Macro Economics (University of Maryland)
- Environmental and Natural Resource Economics (Rutgers)

### **Federal Reserve Experience**

Federal Reserve Bank of Kansas City, *Senior Economist* Jan. 1998 – Aug. 1999; *Economist*, Jan. – Dec. 1997

- Analysis of regional, macroeconomic developments in agriculture, and energy
- Research on public policy towards agriculture in the U.S., especially the impact of farm policy reform
- Briefings to the Bank president and outside groups on the regional economy, agriculture, agricultural trade

Board of Governors of the Federal Reserve System, *Economist*, Jun. 1994 – Dec. 1996

- Analysis of macroeconomic conditions, commodity markets, and prices (CPI, PPI, Core prices)
- Forecasting of agricultural output, prices, and income
- Briefings to the Board of Governors on agriculture and food-price developments

### **Other Consulting Experience**

World Perspectives, Inc., 2003 - 2004

- Analysis of trade barriers for U.S. exports of feed ingredients, pet food ingredients, and food ingredients
- Analysis of the impact of a Free Trade Area of the Americas on U. S. soybean producers
- Analysis of the potential for U.S. Halal-certified meat exports to the Middle East

Womble Carlyle Sandridge & Rice, LLP, 2003 - 2004

- Provided expert testimony related to the estimation of business profitability Smith-Moore, 2002 - 2003
- Provided economic analysis of the U.S. Tobacco Program

Superintendencia de Banca y Seguros (Lima, Peru), 1998 - 2000

- Developed and taught a class on Microfinance issues (in English) to students enrolled in a training program for bank examiners; the program was sponsored by the Inter-American Development Bank.

World Bank, Africa Technical Department, 1992 – 1993

- Summarized and provided an overview of data available on African economic and social indicators

ACG-Afrique, January 1993

- Provided critical review of a study document outlining the impact of structural adjustment on African agriculture

### **Professional Organizations**

- National Association for Business Economics
- American Economic Association

### **Papers, Publications, and Speeches**

#### **Papers Published in Refereed Journals**

- “Losing the Forest for the Trees: On the Loss of Economic Efficiency and Equity in Federal Price-Fixing Class Actions,” (with Martin A. Asher and Gregory K. Arenson) *Virginia Law & Business Review*, Vol. 16, No. 2, Spring 2022, 293-325
- “Government Regulation and Quality in the U.S. Beef Market,” (with Peyton Ferrier) *Food Policy*, Vol. 32, No. 1, February 2007, 84-97
- “Rent-seeking in U.S.-Mexican Avocado Trade,” *Cato Journal*, Vol. 26, No. 1, December 2006, 159-177
- “Consolidation in U.S. Agriculture and the Role of Public Policy,” *The ICFAI Journal of Agricultural Economics*, Vol. 1, 2004, 7-16
- “Fertilizer Use, Risk, and Off-farm Labor Markets in the Semi-Arid Tropics of India,” *American Journal of Agricultural Economics*, Vol. 85, No. 2, May 2003, 359-371
- “Inverse Productivity: Land Quality, Labor Markets, and Measurement Error,” *Journal of Development Economics*, Vol. 71, No. 1, June 2003, 71-95
- “A Market-Forces Policy for the New Farm Economy?” *Review of Agricultural Economics*, Vol. 24, No. 1, 1 March 2002, 15-30
- “Food Crops, Exports, and the Short-run Policy Response of Agriculture in Africa,” *Agricultural Economics*, Vol. 22, No. 3, April 2000, 271-298
- “FAIR Act Implications for Land Values in the Corn Belt,” (with Jason Henderson) *Review of Agricultural Economics*, Vol. 22, No. 1, Summer – Spring 2000, 102-119
- “Why are Estimates of Agricultural Supply Response So Variable?” (with Francis X. Diebold) *Journal of Econometrics*, Vol. 76, No. 1-2, January – February 1997, 367-373

#### **Non-refereed Publications, Articles, and Editorials**

- “The Predominance Requirement for Antitrust Class Actions – Can Relevant Market Analysis Help?” (with Jeffrey Leitzinger) American Bar Association – Section of Antitrust Law, *Economics Committee Newsletter*, Vol. 7, No. 1, Spring 2007, 17-22
- “Reform of U.S. Farm Policy in an Integrating World Economy,” *Developing Countries in the WTO System*, 2006

- “New Farm Economy,” *Regulation*, Winter 2003-2004, Cato Institute for Public Policy Research, 2003
- “What Road Will U.S. Economy Take in 2003?” *Southeast Farm Press*, 5 February 2003
- “Fast Track for the Tax Cuts,” guest editorial, *News and Observer*, 18 January 2003
- “The 2002 Farm Bill,” (with Blake Brown and Michele Marra) *NC State Economist*, November – December 2002
- “Economy-minded Tax Cuts: Bush's Reductions Provided the Boost to Lift U.S. From Recession,” guest editorial, *News and Observer*, 2 July 2002
- “Policy Only Effective if Farm Economy is Recognized,” special report to *Feedstuffs*, 5 June 2000
- “Aid During Crisis of Little Long-term Help to Farmers,” guest editorial, *Kansas City Star*, 23 August 1999
- “Survey of Agricultural Credit Conditions,” Federal Reserve Bank of Kansas City, *Regional Economic Digest*, various issues, 1997-1999
- “U.S. Agriculture at the Crossroads in 1999,” *Economic Review*, Federal Reserve Bank of Kansas City, Vol. 84, No. 1, 1999, 73-91
- “Can U.S. Oil Production Survive the 20th Century?” *Economic Review*, Federal Reserve Bank of Kansas City, Vol. 84, Quarter I, 1999
- “Will the Tenth District Catch the Asian Flu?” (with Ricardo Gazel) *Economic Review*, Federal Reserve Bank of Kansas City, Vol. 83, Quarter II, 1998, 9-26
- “From the Plains to the Plate: Can the Beef Industry Regain Market Share?” (with Michelle Beshear) *Economic Review*, Federal Reserve Bank of Kansas City, Vol. 83, Quarter IV, 1998, 49-66
- “U.S. Agriculture: Another Solid Year in 1998?” (with Mark Drabenstott) *Economic Review*, Federal Reserve Bank of Kansas City, Vol. 83, No. 1, Quarter I, 1998, 55-74
- “How Will the 1996 Farm Bill Affect the Outlook for District Farmland Values?” *Economic Review*, Federal Reserve Bank of Kansas City, Vol. 82, Quarter IV, 1997, 85-101
- “Food Prices and the Farm Sector,” monthly *Greenbook*, Federal Reserve Board of Governors, various issues 1994-1996
- “Hedge to Arrive Contracts,” Memo to the Board of Governors, Federal Reserve Board of Governors, 5 June 1996
- “Prices in the May Greenbook,” Federal Reserve Board of Governors, 19 May 1996
- “Prices in the March Greenbook,” Federal Reserve Board of Governors, 24 March 1996
- “Commodity Price Developments,” Weekly memo to the Board of Governors, Federal Reserve Board of Governors, August 1994 – December 1996

### **Conference Presentations**

- “Class Action Developments,” panelist at the American Antitrust Institute’s 6<sup>th</sup> Annual Private Antitrust Enforcement Conference, Washington, DC: 4 December 2012
- “Consequences for Antitrust Thought and Practice,” presented at the American Antitrust Institute Invitational Symposium: Antitrust Challenge of Multi-Channel Distribution in the Internet Age, Washington, DC: 22 June 2011
- “The U.S. Economy in the Year Ahead,” presented at the Long Company Annual Conference, Chicago, IL: 11 September 2009 and 19 September 2008
- “The U.S. Economic Outlook,” presented at the Industry Outlook Conference, Chicago, IL: 17 October 2006 and 18 October 2005
- “How Will the Economy Impact Your Business?” presented at the Long Company Annual Conference, Las Vegas, NV: 14 August 2004
- “Focus on The Economy” presented at *Milling and Baking News* Annual Purchasing Managers’ Conference, Kansas City, MO: 14 June 2004, 10 June 2003 and 11 June 2002
- “The U.S. Economic Outlook and Agriculture,” presented at the Industry Outlook Conference, Chicago, IL: October 2003
- “The U.S. Economic Outlook and Agriculture,” presented at the Industry Outlook Conference, Breckenridge, CO: 7 April 2002
- “The U.S. Economic Outlook: The Cost of Terror,” presented at the Southern Agricultural Outlook Conference, Atlanta, GA: 24 September 2001
- “The Economy in Focus,” presented at *Milling and Baking News* annual purchasing managers’ conference, Kansas City, MO: 5 June 2001
- “The Great American Growth Machine,” presented at the Southern Agricultural Outlook Conference, Atlanta, GA: 27 September 2000
- “The Economy in Focus,” presented at *Milling and Baking News* annual purchasing managers’ conference, Kansas City, MO: 6 June 2000
- “The Outlook for the U.S. Pork Sector,” presented to the Industry Outlook Conference, Las Vegas, NV: 17 April 2000
- “The National Economic Outlook: The Road Ahead,” presented to the Food Industry Outlook Conference, Breckenridge, CO: 11 April 1999
- “Farm Policy for the New Millennium,” presented to Federal Reserve Bank of Kansas City, Division of Bank Supervision and Regulation, Bank Examiners’ Annual Training Conference, 7 January 1999
- “The Impact of the 1996 Farm Bill on Farmland Values,” (with Jason Henderson) first place poster presentation at the annual meetings of the American Agricultural Economics Association, Salt Lake City, UT: 4 August 1998

- “A Note on the Inverse Productivity Relationship,” presented at the annual meetings of the Western Economic Association International, Seattle, WA: July 1997
- “Off-farm Labor Supply and Fertilizer Use in the Semi-Arid Tropics of India,” presented at the annual meetings of the American Agricultural Economics Association, August 1995
- “Prices for Food-Away-From-Home and Core Inflation: Some Empirical Relationships,” (with James E. Kennedy) presented at the Federal Reserve System Committee on Agriculture, Richmond, VA: October 1995
- “Some Simple Dynamics of Farming,” presented at the annual meetings of the American Agricultural Economics Association, Orlando, FL: August 1993
- “Structural Adjustment and Food Security,” (with W. Graeme Donovan), presented at the annual meetings of the American Agricultural Economics Association, Orlando, FL: August 1993
- “Structural Adjustment and African Agricultural Supply Response to Exchange Rate and Price Movements,” (with W. Graeme Donovan), presented at the annual meetings of the Southern Agricultural Economics Association, Tulsa, OK: January 1993

#### **Other Presentations**

- Panelist, “Injured V. Non-Injured In Class Actions,” American Bar Association, 18 October 2022
- Panelist, “If I Am Uninjured, Do I Not Bleed? The Packaged Seafood Decision,” American Bar Association Webinar, 22 June 2022
- Panelist, “Antitrust Class Actions – Where Are We? A 360 Degree Perspective,” NYSBA Annual Antitrust Law Section Meeting,” 30 January 2014
- Panelist, Retrospective on the Baby Products Litigation, ABA Section of Antitrust Law: Pricing Conduct Committee, 31 July 2013
- Panelist, Economic Forecasting Summit, Northern Indiana Workforce Investment Board, Inc., 29 March 2007
- “The Welfare Benefits of USDA Beef Quality Certification Programs” (with Peyton Ferrier), presentation memo, 2007
- “Reform of U.S. Farm Policy in an Integrating World Economy,” presented to the Cordell Hull Institute, Trade Policy Roundtable on Reform of U.S. Farm Policy and the WTO System, Washington, DC: 31 March 2006
- “The Case for a Market-forces Farm Policy in the U.S.” presented at the Cordell Hull Institute Trade Policy Roundtable, Washington DC: 26 May 2005
- “How Will the Economy Impact Your Business?” presented at the Apple Processors Association annual meeting, Homewood Resort, 20 June 2004
- “The U.S. and International Economic Outlook,” presented at the AgFirst Loan Officer’s Seminar, Atlanta, GA: 30-31 October 2002

- “Will the U.S. Economy Bounce or Crawl?” presented to the Eastern Bankruptcy Institute, North Myrtle Beach, SC: 1 June 2002
- “The U.S. Economic Outlook and Agriculture,” presented to the National Pork Producers Pork Action Group, Washington, DC: 10 April 2002
- “The U.S. Economic Outlook” presented to the Risk Management Associates, Raleigh, NC: 7 February 2002
- “The U.S. Economic Outlook: The Cost of Terror,” presented at the National Pork Producers Pork Action Group, Marco Island, FL: 14 November 2001
- “Consolidation in Agriculture and the Role of Public Policy,” paper presented to the Southern Extension Meetings, Williamsburg, VA: 13 June 2000
- “The New Farm Economy,” presented at the annual meetings of the National Association of County Agricultural Agents, Omaha, NE: 14 September 1999
- “Regional Economic Update,” presented to bankers in Kansas, Nebraska, Missouri, and Oklahoma as part of the Regulatory Update Seminar, Federal Reserve Bank of Kansas City, April 1999
- “The National Economic Outlook,” presented to Oklahoma State University Advanced Cattle Management Seminar, Stillwater, OK: 11 March 1999
- “Regional Economic Update,” presented to Thomas Hoenig, President, Federal Reserve Bank of Kansas City, 13 November 1998
- “Can the Tenth District Survive the Asian Flu?” The Federal Reserve Bank of Kansas City Economic Forums, nine presentations to bankers in Wyoming, Oklahoma, and New Mexico, 21 September – 21 October 1998
- “The Impact of Asian Economic Developments on Tenth District Agriculture,” presented to Thomas Hoenig, President, Federal Reserve Bank of Kansas City, 30 January 1998
- “The Outlook for the Nebraska Economy,” The Federal Reserve Bank of Kansas City: Nebraska Economic Forums, six presentations to bankers in Nebraska, 6-15 October 1997
- “Update on the Macroeconomy and Special Briefing on Forecast Performance at the Kansas City Fed,” presented to Thomas Hoenig, President, Federal Reserve Bank of Kansas City, 13 August 1997
- “Regional Economic Update,” presented to Thomas Hoenig, President, Federal Reserve Bank of Kansas City, 14 May 1997 and 21 March 1997
- “Producer Prices, Retail Sales, and Agricultural Commodity Markets,” presented to the Board of Governors of the Federal Reserve System, 15 July 1996

## **Referee Experience**

### **Referee for the Following Academic Journals**

- World Development, 1993
- Journal of Development Economics, 1994, 1995
- International Economic Review, 1995
- Journal of Human Resources, 1997
- Journal of Business and Economics Statistics, 1997
- American Journal of Agricultural Economics, 1999, 2001, 2002
- Agricultural Economics, 2000, 2001, 2004
- Agricultural Finance Review, 2000, 2004
- Review of Agricultural Economics, 2000, 2002, 2004
- Journal of Agricultural and Resource Economics, 2000, 2001, 2002
- Emerging Markets Review, 2001
- Contemporary Economic Policy, 2004

## **Fellowships, Honors, and Awards**

### **Fellowships**

- Departmental Fellowship, University of Pennsylvania, 1989-1990
- Dean's Fellowship, University of Pennsylvania, 1991-1992
- Graduate School Fellowship, University of Maryland, College Park, 1987-1989

### **Honor Societies and Professional Organizations**

- Phi Eta Sigma National Honor Society
- Mortar Board National Honor Society
- Golden Key National Honor Society
- Vice President for Professional Activities, Delta Sigma Pi

### **Awards**

- Top Graduate in Liberal Arts, University of Tennessee, Knoxville, Spring 1987
- Chancellor's Citation for Extraordinary Professional Promise, University of Tennessee, Knoxville
- Chancellor's Citation for Outstanding Academic Achievement, University of Tennessee, Knoxville
- First place poster presentation, American Agricultural Economics Association annual meetings, August 1998 (with Jason Henderson)

- Honorable mention, American Agricultural Economics Association, Essay for the 21<sup>st</sup> Century, 2001, “A Market Forces Policy for the New Farm Economy”
- Honorable mention, American Antitrust Institute Antitrust Enforcement Awards, Outstanding Antitrust Litigation Achievement in Economics (for work in *In Re Titanium Dioxide Antitrust Litigation*)
- American Antitrust Institute Antitrust Enforcement Awards, Outstanding Antitrust Litigation Achievement in Economics (for work in *In Re Domestic Drywall Antitrust Litigation*)
- American Antitrust Institute Antitrust Enforcement Awards, Outstanding Antitrust Litigation Achievement in Economics (for work in *In Re Namenda Direct Purchaser Antitrust Litigation*)

### **External Funding**

- “Unmanufactured Flue-Cured Tobacco Exports and the Export Component of the Quota Formula.” \$13,890 NC Tobacco Foundation. With Blake Brown 2000 – 2001.

### **Professional Activities and Services**

#### **Graduate Student Advising**

M.A. degree, North Carolina State University

- Joe Weinberg (Political Science)

Master of Economics, North Carolina State University

- William Pole (2000)
- Dwight Wilder (Chairman, 2002)
- Adrian Atkeson (2002)
- Sarah Spivey
- Li Zhang (Chairman, 2003)
- Nia Atmadja (2003)

Doctor of Philosophy, North Carolina State University

- William Deese (2003)
- Peyton Ferrier (Chairman, 2004)
- Yang Wang (2003)
- Bobby Huggett (2003)
- Syed Wadood (Chairman, 2004)
- Henry Kuo

### **Economic and Statistical Modeling Skills**

- Experience with all major statistical software including SAS, STATA, LIMDEP and C++; applied econometric modeling skills in damage analysis of consumer industries,

chemicals industries, and agricultural markets, correlation analysis for class certification.